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ENHANCED CORD BLOOD (CB) NATURAL KILLER CELL (NK) EXPANSION,
ACTIVATION AND CYTOLYTIC ACTIVITY BOTH IN-VITRO AND IN-VIVO
FOLLOWING STIMULATION WITH GENETICALLY ENGINEERED
K562MBIL15-41BBL (MODK562)
Ayello, J.1, Hochberg, J.2, Zhao, F.1, Vandeven, C.1, Levin, M.1,
Quish, W.1, Stier, A.1, Cairo, M.S.1 1Columbia University, New York,
NY; 2New York Medical College, Maria Fareri Children’s Hospital, Val-
halla, NY
NK cells appear to play a significant role in reducing relapse in
pts with hematological malignancies following AlloSCT (Dunbar
et al. Haematologica 2008). NK therapy limitations include lack of
tumor recognition and limited cell numbers (Shereck/Cairo et al.
Ped Bld Can 2007). We demonstrated a 35-fold increase in NK
number when CBMNC are expanded (E) with MODK562
(Ayello/Cairo et al. ASH 2010). We evaluated the cytolytic mech-
anisms, invitro and invivo cytolytic activity in NODSCID mice
xenografted with human BL and treated with MODK562 (gener-
ously supplied by D.Campana MD, PhD) stimulated CBMNC.
After 100GY irradiation, MODK562 and wildtype (WT) K562
were cultured with CBMNC in RPMI1IL-2 for 7d. NK activa-
tion LAMP-1, perforin and granzyme B were determined by
flow cytometry and cytotoxicity by europium release assay at
20:1 E:T ratio with Ramos (BL), K562 (NK sensitive) and
SUDHL-6 (DLBCL) tumor targets. Mammalian expression con-
struct, ffLUCZeo-pcDNA, (generously supplied by L.Cooper
MD, PhD) was transfected into BL cells. 6-wk old NODSCID
(NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ) mice received 5x106 BL cells
IP, then treated with: PBS, BL only, 5x106 CBMNC WTK562E,
5x106 MODK562E or 5x107 MODK562E, IP for 5 wks. Tumor
growth was monitored by volume, bioluminescent imaging and
survival for 10 weeks. After 7d, MODK562 ECBMNC showed in-
creased granzyme B and perforin expression compared to
WTK562 (226.5 vs 116.3%, p \ 0.001; 4261.5 vs 156.5,p \
0.001, respectively) and increased NK activation (p \ 0.05).
MODK562 ECBMNC cytotoxicity was significantly increased
compared to WTK562 against K562 (p\ 0.001), BL (p\ 0.01)
and DLBCL (p \ 0.01) targets. At 5 wks, tumor volume in
mice receiving either dose of MODK562 was decreased compared
to WTK562 (260.6 and 0.46.05 vs 36 0.25/mm3, p 5 0.0086
and p 5 .0001, respectively). Tumor luminescence was decreased
in mice treated with either MODK562 ECBMNC compared to
WTK562 (p \ 0.01). At 10 wks, mice treated with 5x107
MODK562 ECBMNC showed significantly increased survival
than WTK562 (p \ 0.001). Thus, CBMNC stimulated with
MODK562 was associated with significant marker expression in-
crease of NK activation, LAMP-1, perforin and granzyme B gran-
ule exocytosis, enhanced invitro cytotoxicity and increased
survival in a human/mouse xenograft model. Future directions in-
clude CAR CD20 (CD20 (MSCV-anti-CD20-41BB-CD3£) trans-
duction into MODK562 ECBMNC to target against CD201
hematologic malignancies to evaluate enhanced tumor targeting
cytolytic activity.Table 1. Product characteristics and engraftment parameters
G (n526)
CD 34+ dose (x 106/kg) –Mean +/- SD 4.41 +/- 1.3
CD 34+ dose (x 106/kg) – Median (IQR) 4.21 (3.35-4.81)
CFU-GM (x 105/kg) – Median (IQR) 9.08 (7.58-11.42)
CFU-GM/CD34+ ratio– Median (IQR) 0.22 (0.19-0.29)
Neutrophil engraftment (days) – Median (IQR) 12 (12-13)
Platelet engraftment (days) – Median (IQR) 12 (11-12.75)
D100 white blood cell count(103/mm3) – Median (IQR) 5.19 (3.90-7.10)
D100 neutrophil count (103/mm3) – Median (IQR) 3.11 (2.29-3.82)
D100 platelet count (103/mm3) – Median (IQR) 155 (119-186)
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Introduction: The dose of CD341 cells/kg in the mobilized
PBHSC product is regarded as the main determinant of neutrophil
and platelet engraftment after AHSCT. Whether the method of
HSC mobilization, namely G-CSF alone (G), G-CSF 1 plerixafor
(G1P) or cyclophosphamide 1 G/GM-CSF (Cy1G/GM), inde-
pendently affects CFU-GM capacity, engraftment, and graft func-
tion is unknown.
Methods: We used a database of AHSCT patients with multiple
myeloma (MM) or lymphoma (Ly) to define 3 groups with differ-
ent mobilization strategies (G, G1P, and Cy1G/GM) but receiv-
ing similar CD341 cell doses. Imbalances in cell doses across the
three groups were resolved by elimination from the analysis
patients with extremes of CD341 doses (without investigator
awareness of the engraftment endpoints) so all groups had similar
distribution of CD341 doses. The three groups were compared in
terms of CFU-GM, ratio of CFU-GM/CD341, and engraftment
of neutrophils and platelets. Comparisons of sustained graft
function were based on complete blood counts on or near day
100.
Results: The initial database contained 123 (70 MM and 53 Ly)
patients undergoing AHSCT in the three groups (26 G, 38
G1P and 59 Cy1G/GM). After correction for imbalances in
CD341 dose, 96 patients remained in the analysis (26 G, 32
G1P and 38 Cy1G/GM). Median CD341 cell dose was 4.21/
kg (interquartile range (IQR) 3.35-4.81), 4.11/kg (IQR3.41-
6.36), and 4.67/kg (IQR4.17-5.34) for G, G1P and Cy1G/GM
respectively. There was no significant difference in number of
CFU-GM between the three groups, however ratio of CFU-
GM/CD341 was significantly lower for G1P (table). Neutrophil
engraftment was significantly slower for G1P with median days
to engraftment of 13 (IQR 12-15) versus 12 (IQR12-13) and 12
(IQR11.25-12) for G and Cy1G/GM respectively (p 5 0.028).
Platelet engraftment was also delayed for G1P with median num-
ber of days to engraftment of 14.5 (IQR11-18) versus 12 (IQR11-
12.75) and 11 (IQR10-14) for G and Cy1G/GM respectively (p
5 0.012). At day 100, there was no difference in graft function
among the groups.
Conclusion: PBHSC products obtained via mobilization with
G1P have a slightly reduced capacity to produce CFU-GM in vi-
tro and are associated with a minimal delay in engraftment that is
independent of CD341 cell dose. It is unknown whether this effect
is determined by plerixafor itself or by conditions leading to pler-
ixafor use. Sustained graft function is not affected by mobilization
strategy.Mobilization Strategies
G+P (n532) Cy+G (n538) P value
4.93 +/- 1.9 4.60 +/- 1.02 0.375
4.11 (3.41-6.36) 4.67 (4.17-5.34) 0.433
7.41 (5.89-12.63) 10.88 (7.27-18.30) 0.081
0.19 (0.14-0.23) 0.24 (0.18-0.37) 0.008
13 (12-15) 12 (11.25-12) 0.028
14.5 (11-18) 11 (10-14) 0.012
4.38 (3.5-5.64) 4.98 (4.17-6.19) 0.172
2.34 (1.89-3.04) 2.92 (2.04-4.26) 0.117
141 (118-201) 156 (92-209) 0.947
